Skip to content Skip to sidebar Skip to footer

Biogen 'could migrate' from neuroscience to immunology, with $10B 'dry powder'

admin 25 April 2023 0Comments

Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday. | Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday.

0Likes

Biogen 'could migrate' from neuroscience to immunology, with $10B 'dry powder'

Leave a comment Cancel reply

You May Also Like

Biogen Inc. (NASDAQ:BIIB) Given Consensus Rating of “Moderate Buy” by Analysts

Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M

Unlock the Future of Pharma: Empower Your Journey with Medicalgogo's AI-Powered Solutions

Newsletter Signup

Quick Links

Space

Contact Us